Autres langues Regeneron Pharmaceuticals, Inc.

Actions

REGN

US75886F1075

Temps Différé Nasdaq Autres places de cotation 22:00:00 29/09/2023			Varia. 5j.	Varia. 1 janv.
822.96 ^USD	-1.39%		-0.23%	+14.06%

29/09	Regeneron annonce que la FDA américaine a accepté d'examiner en priorité la demande de licence biologique de l'odronextamab, un médicament candidat contre le lymphome	MT
29/09	Regeneron Pharmaceuticals, Inc. annonce que la Food and Drug Administration (FDA) des États-Unis a accepté la demande de licence biologique d'odronextamab pour le traitement du lymphome folliculaire récidivant/réfractaire et du lymphome diffus à grandes cellules B dans le cadre d'une évaluation prioritaire	CI

Autres langues

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma for Priority Review	29/09
Regeneron Says US FDA Accepts for Priority Review Lymphoma Drug Candidate Odronextamab's Biologics License Application	29/09
Regeneron Gets FDA Priority Review of Odronextamab in Follicular, Diffuse Large B-cell Lymphoma	29/09
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review	29/09
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023	28/09
Regeneron to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on November 2, 2023	28/09
Regeneron Pharmaceuticals, Inc. acquired remaining 91.65% stake in Decibel Therapeutics, Inc. from a group of shareholders.	25/09
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review	26/09
Allergic Rhinitis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)	28/09
REGENERON PHARMACEUTICALS, INC. - DUPIXENT SBLA FOR TREATMENT OF EOSINOPHILIC ESOPHAGITIS IN CHILDREN AGED 1 TO 11 ACCEPTED FOR FDA PRIORITY REVIEW	26/09
Ultragenyx Pharmaceutical Gets Canadian Approval for Severe Hypercholesterolemia Treatment	26/09
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Application for Priority Review	26/09
Sanofi, Regeneron Obtain US FDA's Priority Review Tag for Esophagus Disease Drug	26/09
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review	26/09
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review	26/09
Ultragenyx Says the Cholesterol Evkeeza Gets Canadian Approval	25/09
Regeneron Pharmaceuticals Completes Acquisition of Decibel Therapeutics	25/09
Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss	25/09
AbCellera Expands Antibody Discovery Collaboration With Regeneron	20/09
Sandoz dials up product launch plans ahead of market debut	15/09

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse

Filtres

A la une

Focus : EuroAPI, la pharma par les ingrédients

Le 14 juin 2022 à 15:53